Radiopharmaceutical composition targeting glypican 3 and its use
Radiopharmaceutical conjugates with GPC3-binding peptides and radionuclides offer improved therapeutic efficacy by specifically targeting GPC3-expressing tumors, addressing the limitations of existing GPC3-targeting therapies.
JP2026520154APending Publication Date: 2026-06-22RAYZEBIO INC
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2025570864
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-07
- Filing Date
- 2024-06-06
- Publication Date
- 2026-06-22
AI Technical Summary
Technical Problem
Current therapies targeting glypican 3 (GPC3) expression in tumors, such as the GC33 antibody, have shown limited efficacy in clinical trials, necessitating the development of more effective GPC3-binding agents for cancer treatment.
Method used
Development of radiopharmaceutical conjugates comprising peptides with specific avidity to GPC3, covalently bonded to a metal chelating agent capable of binding radionuclides, which can be used to target and treat GPC3-expressing tumors.
Benefits of technology
The radiopharmaceutical conjugates provide enhanced targeting and therapeutic efficacy by delivering radionuclides specifically to GPC3-expressing tumors, potentially improving treatment outcomes for cancers like hepatocellular carcinoma.
✦ Generated by Eureka AI based on patent content.
Abstract
Radiopharmaceuticals and conjugates targeting GPC3, as well as their compositions and uses, are provided herein. In one embodiment, a conjugate comprising a peptide having avidity to GPC3 and a metal chelating agent configured to bind to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. The conjugate described herein may further comprise a radionuclide. In one embodiment, a radiopharmaceutical comprising a peptide and a metal chelating agent binding to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. Methods for treating cancer by administering the radiopharmaceuticals, conjugates, and compositions thereof are further provided herein.
Need to check novelty before this filing date? Find Prior Art